BioMedNewsBreaks

WednesdayOct 07, 2026 10:40 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (NASDAQ: VRXA) , a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration “FDA”-aligned New Approach Methodologies “NAMs” across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines and significantly reduce animal testing. VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates. VERAXA said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived…

Continue Reading

TuesdayOct 06, 2026 11:40 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD(TM) Clinical Research Business. Quantum BioPharma said the randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an…

Continue Reading

TuesdayOct 06, 2026 9:00 am

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV-105 in Prostate Cancer

Kairos Pharma (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The analysis showed a statistically significant difference in progression-free survival, with median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared with two months for those receiving apalutamide alone (P=0.0008). Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression, with patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor to be randomized to enzalutamide alone or enzalutamide in…

Continue Reading

MondayOct 05, 2026 12:03 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens BIO REBOOT Registration, Announces PDAOAI Presentations at Drug Discovery 2026 

Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. Participants can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community, with selected projects potentially considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning and clinical development. Oncotelic also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will…

Continue Reading

MondayOct 05, 2026 9:50 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Provides Update on Phase II Ebola Trial of NV-387 Oral Gummies

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, provided additional details on its Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus "BDBV" outbreak and other Ebola viruses in the Democratic Republic of Congo. The company said the trial is proceeding as designed, with enrollment in Phase IIA beginning on or about Sept. 23, 2026. Phase IIA is intended to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy. Pasted markdown NanoViricides said NV-387 is designed to…

Continue Reading

ThursdayOct 01, 2026 11:56 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Selects DRCARE247 as Telemedicine Partner

HealthLynked (OTCQB: HLYK) , a healthcare technology company focused on AI-powered patient engagement, care coordination and provider connectivity, selected DRCARE247 as its telemedicine partner. The partnership will integrate virtual care into the HealthLynked mobile application and website, allowing users to move from AI-powered health guidance to provider discovery, appointment scheduling, virtual consultations and medical record management within a single platform. HealthLynked expects to begin launching the integrated telemedicine platform in selected geographic regions over the next three months, followed by expansion into additional U.S. markets, subject to provider availability and applicable state requirements. The integration is expected to work alongside…

Continue Reading

ThursdayOct 01, 2026 9:00 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced the closing of its previously announced registered direct offering of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. The offering generated approximately $4 million in gross proceeds before fees and expenses. In a concurrent private placement, Lantern issued unregistered warrants to purchase up to 3,669,725 shares at an exercise price of $1.09 per share, potentially providing an additional approximately $4 million in gross proceeds if fully exercised for cash. The company intends…

Continue Reading

WednesdaySep 30, 2026 3:50 pm

BioMedNewsBreaks — Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Preps ONC010 for Clinical Translation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its preclinical oncology candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms involved in cancer survival and treatment resistance, while building the manufacturing, regulatory and financial infrastructure needed for clinical development. The company reports completing a 300-gram API scale-up with approximately 99.3% purity, expanding manufacturing capabilities through a partnership with Nanosoft Polymers, and progressing metabolism, analytical, licensing and other IND-enabling activities. It has also arranged approximately CAD$5 million in institutional financing, to be released through 18 monthly tranches, to…

Continue Reading

WednesdaySep 30, 2026 10:39 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast 

Quantum BioPharma (NASDAQ: QNTM) Co-Founder and Executive Co-Chair Anthony Durkacz returned to The BioMedWire Podcast to discuss the company’s Lucid-MS drug candidate, which is advancing to a Phase 2 trial in multiple sclerosis patients, as well as the development and commercial opportunity surrounding unbuzzd(TM). Durkacz said Lucid-MS targets myelin and that the upcoming trial will mark the first time the drug is tested in patients with multiple sclerosis. He also highlighted clinical results for unbuzzd(TM), which is designed to accelerate alcohol metabolism, and said Quantum BioPharma owns approximately 20% of the company behind the product and has a 7% royalty…

Continue Reading

TuesdaySep 29, 2026 2:55 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (“ADC”) program beyond the initial discovery phase following the completion of its collaboration with OmniAb, with the company now planning to engineer the final candidate using its antibody-engineering, linker and conjugation technologies and conduct in vitro and in vivo preclinical studies. VXA-222 employs an “AND-gate” design intended to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells, while VERAXA continues developing a broader oncology pipeline spanning ADCs, T-cell engagers and other engineered antibody formats. The company has also filed its first patents covering its BiTAC-TCE and BiTAC-ADC…

Continue Reading